Vascular Medicine最新文献

{"title":"2024-25 Reviewer and Guest Editor Acknowledgements.","authors":"","doi":"10.1177/1358863X251383271","DOIUrl":"https://doi.org/10.1177/1358863X251383271","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251383271"},"PeriodicalIF":3.3,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Femoral arteriovenous concentration differences reveal metabolomic shifts in peripheral artery disease (PAD): A case-control study.","authors":"Tuljo Ööbik, Jaak Kals, Jaan Eha, Mihkel Zilmer, Kalle Kilk, Kaido Paapstel","doi":"10.1177/1358863X251370352","DOIUrl":"https://doi.org/10.1177/1358863X251370352","url":null,"abstract":"<p><strong>Background: </strong>We aimed to investigate metabolomic alterations in peripheral artery disease (PAD) by analyzing blood from the femoral artery and vein, assessing metabolite release/uptake in chronically ischemic lower limbs (PAD group) and nonischemic limbs (controls), and evaluating the representativeness of upper-limb venous samples.</p><p><strong>Methods: </strong>In this exploratory case-control study, 24 patients with PAD (Fontaine IIb and III) and 18 control subjects with stable angina were enrolled. Blood was drawn from the femoral artery and vein, and the antecubital fossa. Metabolomic profiling of serum samples was performed using liquid chromatography and tandem mass spectrometry. We analyzed 560 metabolites, including amino acids and derivatives, acylcarnitines, ceramides, phosphatidylcholines, tri- and diglycerides, cholesteryl esters, sphingomyelins, and fatty acids, as well as 52 metabolic ratios/sums across various biochemical classes.</p><p><strong>Results: </strong>Femoral arteriovenous (AV) concentration differences with in-group significance in at least one group and between-group significance was observed for 47 metabolites and five metabolic sums. Among these, eight metabolic variables in antecubital vein samples were significant. Correlation between AV differences and antecubital vein samples was weak.</p><p><strong>Conclusion: </strong>Using the femoral AV concentration differences of metabolites, we identified significant local metabolomic shifts in the PAD group. Most of these changes were not revealed using traditional upper-limb venous blood sampling. Further study of AV differences could improve the understanding of the pathophysiology of PAD.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251370352"},"PeriodicalIF":3.3,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Saving limbs, saving lives: Managing acute limb ischemia in patients with cancer.","authors":"Yolanda Bryce","doi":"10.1177/1358863X251371015","DOIUrl":"https://doi.org/10.1177/1358863X251371015","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251371015"},"PeriodicalIF":3.3,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk associated with carotid bifurcation plaques producing < 50% stenosis and its modulation by presence of common femoral plaques: A cohort study.","authors":"Andrew N Nicolaides, Andrie G Panayiotou, Maura Griffin, Theodosis Tyllis, Dawn Bond, Niki Georgiou, Efthyvoulos Kyriacou, Costantinos Avraamides, Luca Saba, Elena Critselis, Christiana Demetriou, Despo Ierodiakonou, Annalisa Quattrocchi, Pascale Salameh, Eleni L Tolma, Christos Varounis, Richard M Martin","doi":"10.1177/1358863X251358270","DOIUrl":"https://doi.org/10.1177/1358863X251358270","url":null,"abstract":"<p><strong>Background: </strong>The aims were to determine the 10-year risk of atherosclerotic cardiovascular disease (ASCVD) in individuals free from ASCVD (a) in the presence of carotid bifurcation plaques (CBP) < 3-mm thick and ⩾ 3 mm in comparison to a normal vessel wall and (b) the risk modulation in the presence or absence of additional common femoral bifurcations with plaques (CFBP) in a cohort study.MethodsA total of 1000 subjects aged 58.4 ± 10.5 years, free from ASCVD, were followed up for 15.2 ± 4.9 years (mean ± SD). The primary endpoint was a composite of first time fatal or nonfatal 10-year ASCVD events.ResultsThe 10-year risk of ASCVD was 6% in the absence of carotid plaques; 10% in the presence of unilateral and 23% in the presence of bilateral < 3-mm plaques (adjusted hazard ratio [HR] 1.65 [95% CI 1.11-2.47] and 2.03 [95% CI 1.32-3.00], respectively); and 29% for unilateral and 63% for bilateral 3-5 mm plaques (adjusted HR 2.40 [95% CI 1.41-4.09] and 3.78 [95% CI 1.77-8.06], respectively). In those with unilateral or bilateral < 3-mm CBP in the presence of two CFBP, the 10-year risk of ASCVD was 26% and 37% (adjusted HR 3.01 [95% CI 1.38-6.58] and 2.52 [95% CI 1.55-4.10], respectively). The 10-year risk was 2% in those without CBP or CFBP and 26% in those with two CFBP only.ConclusionsThe presence of a < 3-mm CBP may be associated with a significant ASCVD risk, especially if bilateral. This risk is better defined by the additional presence or absence of two CFBPs.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251358270"},"PeriodicalIF":3.3,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Research priorities for peripheral artery disease: A statement from the Society for Vascular Medicine.","authors":"","doi":"10.1177/1358863X251376531","DOIUrl":"https://doi.org/10.1177/1358863X251376531","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251376531"},"PeriodicalIF":3.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular Disease Patient Information Page: What to expect with endovascular revascularization for peripheral artery disease (PAD).","authors":"Andrew H Schulick, Elizabeth V Ratchford, Joseph M White","doi":"10.1177/1358863X251369466","DOIUrl":"https://doi.org/10.1177/1358863X251369466","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251369466"},"PeriodicalIF":3.3,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking factors affecting progression to CLTI following femoropopliteal endovascular revascularization in symptomatic PAD.","authors":"S Elissa Altin, Jennifer Miao","doi":"10.1177/1358863X251367756","DOIUrl":"https://doi.org/10.1177/1358863X251367756","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251367756"},"PeriodicalIF":3.3,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venoactive drug treatment for patients with pelvic varicose veins: Results of the single-center, randomized, open-label study (VENOTREAT).","authors":"Sergey G Gavrilov, Yekaterina P Moskalenko, Anastasiya S Grishenkova, Sergei V Chubchenko","doi":"10.1177/1358863X251362200","DOIUrl":"https://doi.org/10.1177/1358863X251362200","url":null,"abstract":"<p><p><b>Background:</b> The efficacy of venoactive drug (VAD) treatment for pelvic venous disorder (PeVD) has not been fully investigated. This study was aimed at evaluating the efficacy and safety of different diosmin-containing agents in women with PeVD. <b>Methods:</b> VENOTREAT was a single-center, randomized, open-label study included 150 women with symptomatic PeVD, who were allocated for the 2-month therapy a once-daily intake of: (1) micronized purified flavonoid fraction (MPFF) 1000 mg; (2) diosmin 600 mg, or (3) hesperidin and diosmin combination (HDC) 1000 mg. The effects on chronic pelvic pain (CPP), the time to pain relief, as well as adverse events (AEs) were investigated. <b>Results:</b> Patients receiving MPFF reported a CPP reduction, using visual analog scale (VAS) scores, from 5.7 ± 0.8 to 2.8 ± 0.4 (<i>p</i> = 0.001) by day 7 and its elimination by day 28 in all cases. In the diosmin and HDC groups, the CPP reduction became significant by day 14 (VAS scores from 5.3 ± 0.6 to 3.7 ± 0.3 and from 5.1 ± 0.3 to 3.5 ± 0.2, respectively, both <i>p</i> = 0.001), and pain was eliminated after 2 months in 37 and 35, and decreased in the remaining 13 and 15 patients to VAS scores 1.07 ± 0.2 and 1.1 ± 0.07, accordingly. AEs included headache, nausea, gastralgia, and diarrhea and were reported in 7.3% of cases in general and in 6%, 8%, and 8% of patients in the MPFF, diosmin, and HDC groups, respectively. No serious AEs were observed. <b>Conclusion:</b> VAD treatment is effective and safe for eliminating CPP in PeVD. MPFF provides a faster and greater effect on venous CPP of venous origin. <b>ClinicalTrials.gov Identifier: NCT06584799.</b></p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251362200"},"PeriodicalIF":3.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144971000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel microRNA pathways of impaired angiogenesis in human peripheral artery disease adipose tissue.","authors":"Ross A Okazaki, Syed Hm Rizvi, Rosa Bretón-Romero, Yuxiang Zhou, Robert M Weisbrod, Zhuoheng Li, Melissa G Farb, Alik Farber, Naomi M Hamburg","doi":"10.1177/1358863X251359542","DOIUrl":"https://doi.org/10.1177/1358863X251359542","url":null,"abstract":"<p><p><b>Background:</b> Impaired angiogenic response in peripheral artery disease (PAD) contributes to the progression of tissue ischemia, but methods to evaluate angiogenesis at the tissue level are limited. We describe a novel approach to measure angiogenesis and identify microRNA (miR)-gene pathways utilizing adipose tissue from patients with PAD. <b>Methods:</b> Patients with PAD undergoing infrainguinal bypass surgery or non-PAD control patients undergoing knee replacement surgery were recruited. Subcutaneous adipose tissue was obtained at the time of surgery. In patients with PAD, adipose tissue was taken from both the proximal and the distal ends of the surgical incision. Angiogenic capacity was measured and miR sequencing was performed. Differentially expressed miRs were defined by <i>p</i> < 0.01 and log₂ (fold change) > 1 or < -1. The miRs that correlated with angiogenic capacity and their gene targets were identified. <b>Results:</b> Participants with PAD (<i>N</i> = 10) and control participants (<i>N</i> = 5) were recruited. Capillary sprouting was impaired in distal (<i>p</i> = 0.0014) but not proximal (<i>p</i> = 0.12) PAD adipose tissue. In a subset of samples (controls: <i>n</i> = 4, PAD: <i>n</i> = 6), miR sequencing revealed 56 differentially expressed miRs in distal PAD. Six miRs with a correlation to impaired capillary sprouting and related to angiogenesis using Qiagen Ingenuity Pathway Analysis (IPA) software were identified (miRs 144-3p, 15b-5p, 18b-5p, 20b-5p, 454-3p, and 363-3p). These miRs are predicted to target regulators of angiogenesis including vascular endothelial growth factor A (VEGFA), phosphatase and tensin homologue (PTEN), and cyclin-dependent kinase inhibitor 1A (CDKN1A). <b>Conclusion:</b> Evaluation of ischemic adipose tissue represents a novel approach to gain insight into impaired angiogenesis in PAD. Integration with miR sequencing and target analysis has the potential to identify novel pathways of impaired angiogenesis in PAD.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251359542"},"PeriodicalIF":3.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144971023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: 'A call for patient involvement in peripheral artery disease research priority setting'.","authors":"Mary M McDermott, Daniella Kadian-Dodov, Herbert D Aronow, Joshua A Beckman, Mark A Creager, Heather L Gornik, Nicholas J Leeper, Elsie Ross, Marc P Bonaca","doi":"10.1177/1358863X251363524","DOIUrl":"https://doi.org/10.1177/1358863X251363524","url":null,"abstract":"","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"1358863X251363524"},"PeriodicalIF":3.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}